Elanco Animal Health Inc Q4 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jonathan Block - Stifel Nicolaus and Company, Incorporated - Analyst : Great, thanks. Good morning. Jeff, Zenrelia's is US penetration, slightly ahead of our diligence, if you would. So where do you think this can go by year in '25 and maybe more importantly, what about market share at these practices by year in '25 and also curious, any differences in the international markets for Zenrelia we call the label, is less onerous. And then Todd, I guess I'll just ask my follow up here. The accelerating revenue growth off the 1Q, '25 levels, I think you talked a bit about it, but is that just a function of, called Zenrelia and Credelio Quattro, the contribution ramping. Throughout '25 or you know anything else to call out to give investors or people more comfort with the accelerating constant currency revenue growth off the 1Q, '25 guide? Thanks guys. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 25, 2025 / 1:00PM, ELAN.N - Q4 2024 Elanco Animal Health Inc Earnings Call

Question: Michael Ryskin - BofA Global Research - Analyst : Great. The first, maybe just a follow-up to John's question just now on Zenrelia. But just looking at your innovation contribution for 2025, I mean, first of all, you came ahead for 2024 fourth quarter. So that was really encouraging, but when you raised your '25 innovation numbers by, I think, $30 million at the midpoint, I'm not going to ask for sort of specific point estimates for each of your contributing products. But directionally, what gives you more confidence in that? Any that you can call out, whether that is Zenrelia or your first month of Credelio Quattro versus what's behind that. And I got a follow-up.

Question: Michael Ryskin - BofA Global Research - Analyst : Okay. And then maybe for a follow-up, I think in the prepared remarks, you called out your IO monoclonality (inaudible) 4Q '25 approval but it's not in your guidance on (inaudible). Just given what we see with regulatory clearance to a lot of things, they've taken a little bit longer, frankly, and there's a lot of uncertainty in the registry environment overall. Just what gives you confidence in that this far out? Any color you can provide on how those conversations are going?

Question: Daniel Clark - Leerink Partners - Analyst : Great thank you for taking the question. I was just curious, when you talked about the successes of sampling in Zenrelia thus far, is that causing you to maybe change how you're approaching your sales and marketing strategy for that launch?

Question: Daniel Clark - Leerink Partners - Analyst : Got it. And then just on the point of becoming a first-line treatment, can you share some of the feedback you've been getting on vets? Like can you give some color on how many are using it as a first line treatment site? Thank you.

Question: Andrea Alfonso - UBS Securtiies LLC - Analyst : Hi, good morning, everyone. Thank you so much for taking my question. I did want to touch gears a little bit to sort of asking about how the early launch of Credelio Quattro is going so far. In the prepared remarks, you identified that legacy products were sort of seeing low cannibalization within the portfolio. So curious about just the color of the initial momentum? If you can frame maybe in the commercialization strategy, what might be different this time around as well as appetite for partnering with retailers? And I did have a follow-up question after that.

Question: Andrea Alfonso - UBS Securtiies LLC - Analyst : Great. And just a separate question just probing a little bit more to the Galliprant call out. Maybe if you can just discuss the dynamics of the surge there in the quarter? Is that entirely driven by switchers from another therapy versus those who are new to therapy? And if you could just sort of speak to the durability of that 4Q trend persisting into 2025? Thanks so much, everyone.

Question: Erin Wright - Morgan Stanley & Co. LLC - Analyst : Great, thanks. I follow up on Durm. A follow-up on derm. Have you think about the competitive environment in derm? Have we anticipate new competitors in 2025? Is that embedded in your guidance at this point? And just how can you better with leverage that, I guess, expanding portfolio with the injectable product as well? Can you also remind us how differentiated the injectable IL-31 product will be?

Question: Daniel Clark - Leerink Partners - Analyst : Okay. And then can you speak to the sequential progression for margins here and the cadence of some of those investments that you're making around the commercialization of new products and kind of how to think about sort of those stepped-up investments, I guess, in the first half?

Question: Balaji Prasad - Barclays - Analyst : Hi, good morning and two questions from me. Firstly, a follow-through on IL-31. So this 2025, are we going to only see an approval? Or if I read through the lines, in January where you said that it's coming in 2025, should we also expect a launch? Or is there a meaningful gap between approval to launch? That's one. Two, poultry, a pretty important segment, organic growth rate declined here. Could you maybe then comment on the broader poultry market, the drivers and headwinds that we see here, and any major innovations or changes that we can expect to see in the segment in the near future? Thank you.

Question: Chris Scott - JPMorgan - Analyst : Great, thanks so much. Just a couple of questions for me. Maybe just on the margin dynamics over time. Can you just talk a little bit about as we look beyond '25, how we should think about the cadence of gross margin and operating margin improvement for the business, I guess some of the kind of the headwinds from this year on the gross margin side you kind of fade away and you leverage some of this OpEx investments in a sense like how quickly should we think about those margins stepping up over time? And then my second question was just on Bovaer and just a little bit more color about how to think about that launch curve and maybe compare and contrast a little bit of how you're thinking about that relative to what we saw with Experior? Thank you.

Question: David Westenberg - Piper Sandler Companies - Analyst : Hi, thanks for taking the question. We're up on the hour, so I'll ask both my questions upfront. So just in 2023 during the launch of NexGard Plus, we did see multiple competitors discounting in anticipation of launch. Are you seeing anything like that now? And if so, why is the dynamic here different? Is it maybe because the one NexGard used to be like or still was like kind of more leading product, whereas you're playing, not necessarily from a same market share standpoint? And then just the same thing on Galliprant. If you look at [Remol], you had some starts and stops in the incoming of competition. Is this here really an acceleration point tell you maybe the next competitive launch? Just looking at that in history. And then my second question here is on the biologics manufacturing. You called out [225, 250]. I'm not asking for specifics on the pipeline here, but do you think you can have some first-to-market products in biologics and say, 2027, 2030 kind of time frame, because that is a lot of investment to biologic manufacturing. Sorry, that's a lot of questions.